022200orig1s000 - food and drug administration€¦ · 022200orig1s000 chemistry review(s)...
TRANSCRIPT
![Page 1: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/1.jpg)
CENTER FOR DRUG EVALUATION AND RESEARCH
APPLICATION NUMBER:
022200Orig1s000
CHEMISTRY REVIEW(S)
![Page 2: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/2.jpg)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration Silver Spring, MD 20993
CMC Memo to File
To: NDA Date 4 Jan 2012
Sponsor: Amylin Drug: BYDUREONTM (exenatide LAR) injectable suspension
Subject Approval recommendation Reviewer Dr. Olen Stephens
Pursuant the overall “acceptable” recommendation given on 14-Nov-2011 for the manufacturing facilities by the Office of Compliance, CMC recommends that NDA application 22-200 be approved. All labeling changes have been communicated to the applicant through the clinical project manager. There are no pending CMC review deficiencies. HFD-/Division File HFD-510 HFD-510/P. Dharia Olen Stephens, Ph.D. Chemistry Reviewer Ali Al-Hakim, Ph.D. Branch VII Chief, ONDQA
Reference ID: 3066887
![Page 3: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/3.jpg)
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS01/04/2012CMC recommendation: approval
ALI H AL HAKIM01/04/2012
Reference ID: 3066887
![Page 4: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/4.jpg)
![Page 5: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/5.jpg)
![Page 6: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/6.jpg)
![Page 7: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/7.jpg)
![Page 8: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/8.jpg)
![Page 9: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/9.jpg)
![Page 10: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/10.jpg)
![Page 11: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/11.jpg)
![Page 12: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/12.jpg)
![Page 13: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/13.jpg)
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS10/20/2011CMC Recommendation: Approval
ALI H AL HAKIM10/20/2011I concur.
Reference ID: 3031789
![Page 14: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/14.jpg)
![Page 15: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/15.jpg)
![Page 16: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/16.jpg)
![Page 17: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/17.jpg)
![Page 18: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/18.jpg)
![Page 19: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/19.jpg)
![Page 20: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/20.jpg)
![Page 21: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/21.jpg)
![Page 22: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/22.jpg)
![Page 23: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/23.jpg)
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS09/23/2011Comments to be sent to the applicant in the appendix. CMC recommendation pending.
ALI H AL HAKIM09/23/2011
Reference ID: 3019385
![Page 24: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/24.jpg)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration Silver Spring, MD 20993
CMC Memo to File
To: NDA Date 20 Sep 2010
Sponsor: Amylin Pharmaceuticals, Inc. Drug: BYDUREON® (exenatide extended-
release for injectable suspension) Subject Approval recommendation
Applicant’s submission follows Agency complete response letter
Reviewer Dr. Olen Stephens Pursuant the overall “acceptable” recommendation given on 20-Sep-2010 for the manufacturing facilities by the Office of Compliance and approval recommendation from the microbiology division (22-Jul-2010), CMC recommends that NDA application 22-200 be approved. All labeling changes have been communicated to the applicant through the clinical project manager and have been accepted by the applicant. HFD-/Division File HFD-510 HFD-510/J. Bishai Olen Stephens, Ph.D. Chemistry Reviewer Ali Al-Hakim, Ph.D. Branch Chief, ONDQA
![Page 25: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/25.jpg)
Reference ID: 2838992
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS09/22/2010CMC recommendation for approval
ALI H AL HAKIM09/22/2010
![Page 26: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/26.jpg)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration Silver Spring, MD 20993
CMC Memo to File
To: NDA Date 22 JUL 2010
Sponsor: Amylin Pharmaceuticals, Inc. Drug: BYDUREON® (exenatide extended-
release for injectable suspension) Subject Approval recommendation
Reviewer Dr. Olen Stephens Pursuant the overall “acceptable” recommendation given on 15-JUL-2009 for the manufacturing facilities by the Office of Compliance and approval recommendation from the microbiology division (22-Jul-2010), CMC recommends that NDA application 22-200 be approved. All labeling changes have been communicated to the applicant through the clinical project manager and have been accepted by the applicant. HFD-/Division File HFD-510 HFD-510/J. Bishai Olen Stephens, Ph.D. Chemistry Reviewer Ali Al-Hakim, Ph.D. Branch Chief, ONDQA
![Page 27: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/27.jpg)
ApplicationType/Number
SubmissionType/Number Submitter Name Product Name
-------------------- -------------------- -------------------- ------------------------------------------NDA-22200 ORIG-1 AMYLIN
PHARMACEUTICALS INC
Bydureon (exenatide LAR)
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS07/22/2010
ALI H AL HAKIM07/22/2010
![Page 28: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/28.jpg)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration Silver Spring, MD 20993
CMC Memo to File
To: NDA Date 1 Mar 2010
Sponsor: Amylin Drug: BYDUREONTM (exenatide LAR)
injectable suspension Subject Approval recommendation
Reviewer Dr. Olen Stephens Two outstanding items remained from CMC review #2, a recommendations from the Office of Compliance and the microbiology division:
1. The Office of Compliance has issued an overall “acceptable” recommendation on 1-Mar-2010 for the manufacturing facilities.
2. The microbiology division recommended a “complete response” on 1-Mar-2010 based on deficiencies that negatively impact of the drug product.
Pursuant the microbiology recommendation, the CMC recommendation is that NDA application 22-200 receive a complete response that enumerates deficiencies found in the microbiology review. HFD-/Division File HFD-510 HFD-510/J. Bishai Olen Stephens, Ph.D. Chemistry Reviewer Prasad Peri, Ph.D. Acting Branch II Chief, ONDQA
(b) (4)
![Page 29: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/29.jpg)
ApplicationType/Number
SubmissionType/Number Submitter Name Product Name
-------------------- -------------------- -------------------- ------------------------------------------NDA-22200 ORIG-1 AMYLIN
PHARMACEUTICALS INC
Bydureon (exenatide LAR)
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS03/01/2010CMC recommendation is to issue a complete response pursuant the microbiology recommendation
PRASAD PERI03/02/2010I concur
![Page 30: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/30.jpg)
Bydureon™ (Exanatide) for extended release injectable suspension
NDA 22-200
Summary of the Basis for the Recommended Action
from Chemistry, Manufacturing, and Controls Applicant: Amylin Pharmaceuticals, Inc 9360 Towne Centre Drive.
San Diego, CA 92121-3030 Representative: Dawn Viveash, MD
Vice President, Regulatory Affairs and Safety, Phone: (858) 309-7658 Indication: Treatment of type 2 diabetes Presentation: BYDUREON is intended for patient self-administration. BYDUREON is provided in a single-dose kit containing: one vial of 2 mg exenatide, one vial connector, one prefilled diluent syringe and two needles (one provided as a spare). BYDUREON must be injected immediately after the powder is suspended in the diluent and transferred to the syringe. BYDUREON is administered as a subcutaneous (SC) injection. BYDUREON must not be administered intravenously or intramuscularly EER Status: Recommendation pending 23-Jun-2009 Consults: EA – Categorical exclusion granted under 21 CFR §25.31(c) Methods Validation – Revalidation by Agency will not be requested since the methods
listed are standard. Pharmacology/Toxicology –Acceptable Original Submission: 29-May-2009 Post-Approval CMC Commitments: None In light of the failed BE and IVIVC, future changes to the manufacturing process, scale, and/or site may require clinical studies. Drug Substance: Exenatide (exendin, exendin-4, AC2993, LY2148568) is a 39-amino acid peptide manufactured by
. The structural formula is shown below. Structural Formula: 1His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser39-NH2 Molecular Formula: C184H282N50O60S
(b) (4)
![Page 31: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/31.jpg)
![Page 32: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/32.jpg)
![Page 33: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/33.jpg)
ApplicationType/Number
SubmissionType/Number Submitter Name Product Name
-------------------- -------------------- -------------------- ------------------------------------------NDA-22200 ORIG-1 AMYLIN
PHARMACEUTICALS INC
EXENATIDE LAR
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
PRASAD PERI02/08/2010
![Page 34: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/34.jpg)
![Page 35: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/35.jpg)
![Page 36: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/36.jpg)
![Page 37: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/37.jpg)
![Page 38: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/38.jpg)
![Page 39: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/39.jpg)
![Page 40: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/40.jpg)
![Page 41: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/41.jpg)
![Page 42: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/42.jpg)
![Page 43: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/43.jpg)
![Page 44: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/44.jpg)
ApplicationType/Number
SubmissionType/Number Submitter Name Product Name
-------------------- -------------------- -------------------- ------------------------------------------NDA-22200 ORIG-1 AMYLIN
PHARMACEUTICALS INC
EXENATIDE LAR
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS01/20/2010CMC Recommendation: Approval pending an adequate response from microbiology consult andthe recommendation of OC regarding facilities inspections.
PRASAD PERI01/20/2010I Concur
![Page 45: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/45.jpg)
![Page 46: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/46.jpg)
![Page 47: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/47.jpg)
![Page 48: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/48.jpg)
![Page 49: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/49.jpg)
![Page 50: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/50.jpg)
![Page 51: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/51.jpg)
![Page 52: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/52.jpg)
![Page 53: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/53.jpg)
![Page 54: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/54.jpg)
ApplicationType/Number
SubmissionType/Number Submitter Name Product Name
-------------------- -------------------- -------------------- ------------------------------------------NDA-22200 ORIG-1 AMYLIN
PHARMACEUTICALS INC
EXENATIDE LAR
---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.---------------------------------------------------------------------------------------------------------/s/----------------------------------------------------
OLEN M STEPHENS10/13/2009CMC Recommendation: approvable pending resolution of deficiencies regarding total drug productimpurities and individual drug product impurities
PRASAD PERI10/17/2009
![Page 55: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/55.jpg)
Initial Quality Assessment Pre-Marketing Assessment Division 1 Branch 2
Page 1 of 35
Division of Metabolism and Endocrinology Products
NDA: 22-200
Applicant: Amylin Pharmaceuticals, Inc.
Stamp Date: 05-MAY-2009
PDUFA Date: 05-MAR-2010
Proposed Proprietary Name: BYDUREON
Established Name: Exenatide for injectable suspension
Dosage form and strength: Injection, powder, for suspension, extended release
2 mg
Route of Administration: injection
Indications: Treatment of type 2 diabetes
CMC Lead: Su (Suong) Tran, Branch II/DPA I/ONDQA
ONDQA Fileability: Yes
Comments for 74-Day Letter:
Yes, on the last page.
![Page 56: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/56.jpg)
Initial Quality Assessment Pre-Marketing Assessment Division 1 Branch 2
Page 2 of 35
CONSULTS/ CMC RELATED REVIEWS
COMMENT
Biopharmaceutics Not Applicable CDRH or CBER Not Applicable EA Categorical exclusion request will be assessed by Primary Reviewer. EES EER was sent to Office of Compliance on 12-MAY-2009. OSE Labeling consult request will be sent as part of DMEP’s request. Methods Validation Validation may be requested of FDA labs after test methods are
finalized. Microbiology Review of 1) microbiology controls proposed for the drug substance,
exenatide drug product and diluent, and 2) sterilization and aseptic processing validation for the exenatide drug product and diluent.
Pharm/Tox To be determined by the primary reviewer. A consult review may be needed for the safety evaluation of leachables and impurities.
Summary: [See the discussion in Critical Issues later in this review.]
This is an electronic NDA, filed as a 505(b)(1) application. Reference is made to the approved NDA
21-773 and pending NDA 21-919 for the same drug substance, all NDAs having the same applicant.
The drug product is an extended-release formulation of exenatide for once weekly dosing. The drug
powder is reconstituted with the co-packaged diluent prior to use. The current approved Byetta of
NDA 21-773 (same applicant, same drug substance) is for twice daily dosing.
The new drug product is 2 mg of exenatide w/w) and sucrose ( ) encapsulated in biodegradable
polymer (poly-D,L-lactide-co-glycolide, 50:50) ) microspheres. The
polymer degrades in vivo over time to lactic and glycolic acids and releases the active ingredient by a
combination of diffusion and polymer erosion. The product is a powder in a stoppered vial, co-
packaged in a kit that includes the diluent in a syringe, injection needles, and a vial connector. The
diluent is composed of carboxymethylcellulose sodium, polysorbate 20, monobasic sodium phosphate
monohydrate, dibasic sodium phosphate heptahydrate, sodium chloride, and water for injection.
Immediately after reconstitution, the suspension is administered subcutaneously.
Maximum weekly dose is 2 mg exenatide.
(b) (4) (b) (4)
(b) (4) (b) (4)
(b) (4)
33 pages have been withheld immediately following this page as b4 (CCI/TS)
![Page 57: 022200Orig1s000 - Food and Drug Administration€¦ · 022200Orig1s000 CHEMISTRY REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration](https://reader030.vdocument.in/reader030/viewer/2022040605/5eaae3bc5de81217ba0d2bdc/html5/thumbnails/57.jpg)
---------------------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically andthis page is the manifestation of the electronic signature.--------------------------------------------------------------------------------------------------------------------- /s/---------------------Suong Tran6/16/2009 11:13:45 AMCHEMIST
Ali Al-Hakim6/16/2009 11:32:04 AMCHEMIST